Somatic mutations in myeloid transcription factors and in activated signaling pathway, but not in epigenetic modifier pathway, predict the risk of tratment failure and progression to advanced phase in chronic myeloid leukemia
| Authors | |
|---|---|
| Year of publication | 2022 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation |